HDFN linked to maternal health, age and more in Nordic countries
The clinical characteristics and outcomes of pregnancies at risk of HDFN in Sweden, Finland and Denmark, were analyzed in a study.
The clinical characteristics and outcomes of pregnancies at risk of HDFN in Sweden, Finland and Denmark, were analyzed in a study.
Researchers found a low rate of HDFN prophylaxis with Rh immunoglobulin (RHIG) among Rh-negative pregnant women in India.
Results showed that patients who developed jaundice within 24 hours after birth were less likely to have severe jaundice.
A study found phototherapy, a commonly used treatment for neonatal jaundice, does not lead to systemic inflammation in infants.
A recent case report described how an infant was diagnosed with anti-C HDFN despite not showing physical indicators of HDFN.
Practices for alloimmunization prevention and future HDFN management during medical abortions vary significantly among physicians.
New guidelines were published recently surrounding HDFN prevention during the first trimester of pregnancy.
Nipocalimab, an emerging therapeutic agent for hemolytic disease of the fetus and newborn (HDFN), does not appear to affect vaccine efficacy.
A cohort study of 20 pregnancies complicated by HDFN highlights the correlation between early diagnosis and favorable outcomes.
Determining fetal RhD status early in RhD-negative pregnancies could help prevent the unnecessary administration of anti-D immunoglobulin.